Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
复制标题
DOI：
10.1126/science.284.5415.808
复制
发表时间：
1999-04-30
期刊：
影响因子：
56.9
通讯作者：
Hanahan, D
中科院分区：
文献类型：
--
作者：
Bergers, G;Javaherian, K;Hanahan, D
实体瘤的生长依赖于血管生成。在胰岛细胞癌变（RIP 1-Tag 2）的转基因小鼠模型中，在癌前病变中发生血管生成开关，并且血管生成在进展为扩张性实体瘤和浸润性癌期间持续存在。对RIP 1-Tag 2小鼠进行处理，以比较四种血管生成抑制剂在疾病进展的三个不同阶段的作用。ACM-1470、血管抑制素、BB-94和内皮抑制素在旨在预防癌前病变中的血管生成转换、干预小肿瘤的快速扩张或诱导大终末期癌症消退的试验中均产生了不同的疗效特征。因此，当抗血管生成药物针对癌症的特定阶段时，它们可能被证明是最有效的。
Solid tumors depend on angiogenesis for their growth. In a transgenic mouse model of pancreatic islet cell carcinogenesis (RIP1-Tag2), an angiogenic switch occurs in premalignant Lesions, and angiogenesis persists during progression to expansive solid tumors and invasive carcinomas. RIP1-Tag2 mice were treated so as to compare the effects of four angiogenesis inhibitors at three distinct stages of disease progression. ACM-1470, angiostatin, BB-94, and endostatin each produced distinct efficacy profiles in trials aimed at preventing the angiogenic switch in premalignant lesions, intervening in the rapid expansion of small tumors, or inducing the regression of Large end-stage cancers. Thus, anti-angiogenic drugs may prove most efficacious when they are targeted to specific stages of cancer.